Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Strategic Combinations: Future of OV therapy with reovirus
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5566)
•••
Comment by Noteableon Oct 13, 2021 5:31pm
186 Views
Post# 34003017

RE:RE:Strategic Combinations: Future of OV therapy with reovirus

RE:RE:Strategic Combinations: Future of OV therapy with reovirusOctober 07, 2021 -

Crosstalk Between the Tumor Microenvironment and Cancer Cells: A Promising Predictive Biomarker for Immune Checkpoint Inhibitors

T-Cell Infiltration and Activation Within the TME Are Key Drivers of Anti-tumor Immune Response

[This work supports/confirms ONCY's TiLs clonality biomarker findings including that a major factor involved in initial resistance to immune checkpoint inhibitors is the lack or paucity of tumor T cell infiltration, characterizing the so-called “cold tumors” and that being able to identify patients with low levels of TiLs are those patients that positively response to ONCY's OV pelareorep + immune checkpoint inhibitors (ICIs) by ONCY's pelareorep being able to turn cold tumors "hot" thus priming the innate and adaptive immune system in advance of combining pelareorep with ICI therapy. ]
 

https://www.frontiersin.org/articles/10.3389/fcell.2021.738373/full 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities